chemicallytechFine Chemical TechnologiesТонкие химические технологии2410-65932686-7575MIREA – Russian Technological University (RTU MIREA).10.32362/2410-6593-2024-19-3-214-231FUJWGTchemicallytech-2086Research ArticleCHEMISTRY AND TECHNOLOGY OF MEDICINAL COMPOUNDS AND BIOLOGICALLY ACTIVE SUBSTANCESХИМИЯ И ТЕХНОЛОГИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ И БИОЛОГИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙPROTAC® technology and potential for its application in infection controlТехнология PROTAC® и перспективы ее применения в борьбе с инфекциямиhttps://orcid.org/0009-0004-3043-7438ЗахароваМ. А.ZakharovaM. A.

Захарова Мария Андреевна, аспирант, кафедра  биотехнологии и промышленной фармации

119571, Москва, пр-т Вернадского, д. 6

Maria A. Zakharova, Postgraduate Student, Department  of Biotechnology and Industrial Pharmacy

86, Vernadskogo pr., Moscow, 119571

zaharova_ma@mirea.ruhttps://orcid.org/0000-0001-9735-9690ЧудиновМ. В.ChudinovM. V.

Чудинов Михаил Васильевич, к.х.н., доцент кафедры биотехнологии и промышленной фармации

119571, Москва, пр-т Вернадского, д. 86

Scopus Author ID 6602589900

ResearcherID L-5728-2016

Mikhail V. Chudinov, Cand. Sci. (Chem.), Associate  Professor, Department of Biotechnology and Industrial  Pharmacy

86, Vernadskogo pr., Moscow, 119571

Scopus Author ID 6602589900

ResearcherID L-5728-2016

chudinov@mirea.ruМИРЭА — Российский технологический университет (Институт тонких химических технологий им. М.В. Ломоносова)РоссияMIREA — Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)Russian Federation202406072024193214231Copyright © Zakharova M.A., Chudinov M.V., 20242024Захарова М.А., Чудинов М.В.Zakharova M.A., Chudinov M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.finechem-mirea.ru/jour/article/view/2086

Objectives. To describe the pharmaceutical technology of controlled degradation of protein molecules (PROTAC®, Proteolysis Targeting Chimera), approaches to the design of the PROTAC® molecule, methods of ligand and linker selection and synthesis, as well as the application of this technology in dealing with a variety of diseases and the possible limitations of its use.Results. The review covers 77 sources, mostly from 2020–2023. The review outlines the principle of PROTAC® technology: the construction of a chimeric molecule consisting of three fragments. One fragment specifically binds to the biotarget, another recruits the proteolytic system of the host cell, and the third binds them together. The main areas of the current development of the technology are described herein, as well as the opportunities and limitations of chimeric molecules in the fight against different types of infectious diseases.Conclusion. The potential to use PROTAC® technology to combat cancer as well as neurodegenerative, autoimmune, and infectious diseases is shown.

Цели. Описать фармацевтическую технологию направленной деградации белковых молекул (PROTAC®, PROteolysis TArgeting Chimera), подходы к конструированию молекулы PROTAC®, методы подбора и синтеза лигандов и линкера, а также применение данной технологии в борьбе с различными заболеваниями и возможные ограничения ее использования.Результаты. Обзор охватывает 77 источников, в основном за 2020–2023 гг. В обзоре изложен принцип технологии PROTAC®, который заключается в конструировании химерной молекулы, состоящей из трех фрагментов. Один фрагмент специфически связывается с биомишенью, другой рекрутирует протеолитическую систему клетки-хозяина, а третий связывает их между собой. Описаны направления современного развития технологии, а также возможности и ограничения химерных молекул в борьбе с разными типами инфекционных заболеваний.Выводы. Показаны перспективы использования технологии PROTAC® в борьбе с онкологическими, нейродегенеративными, аутоиммунными и инфекционными заболеваниями.

PROTACубиквитин-протеасомная системалигазы Е3молекулярный дизайнпротивовирусные препаратыPROTACubiquitin-proteasome systemE3 ligasesmolecular designantiviral drugsReferencesSakamoto K.M., Kim K.B., Kumagai A., Mercurio F., Crews C.M., Deshaies R.J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U S A. 2001;98(15):8554–8559. https://doi.org/10.1073/pnas.141230798Sakamoto K.M., Kim K.B., Kumagai A., Mercurio F., Crews C.M., Deshaies R.J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. U S A. 2001;98(15):8554–8559. https://doi.org/10.1073/pnas.141230798Kleiger G., Mayor T. Perilous journey: a tour of the ubiquitinproteasome system. Trends Cell Biol. 2014;24(6):352–359. https://doi.org/10.1016/j.tcb.2013.12.003Kleiger G., Mayor T. Perilous journey: a tour of the ubiquitinproteasome system. Trends Cell Biol. 2014;24(6):352–359. https://doi.org/10.1016/j.tcb.2013.12.003Bekes M., Langley D.R., Crews C.M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 2022;21(3):181–200. https://doi.org/10.1038/s41573-021-00371-6Bekes M., Langley D.R., Crews C.M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 2022;21(3):181–200. https://doi.org/10.1038/s41573-021-00371-6He M., Cao C., Ni Z., Liu Y., Song P., Hao S., et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct. Target. Ther. 2022;7(1):181. https://doi.org/10.1038/s41392-022-00999-9He M., Cao C., Ni Z., Liu Y., Song P., Hao S., et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct. Target. Ther. 2022;7(1):181. https://doi.org/10.1038/s41392-022-00999-9Королева О.А., Дутикова Ю.В., Трубников А.В., Зенов Ф.А., Манасова Е.В., Штиль А.А., Куркин А.В. PROTAC — стратегия развития мишень-направленных лекарств: принципы и ограничения. Известия Академии Наук. Серия химическая. 2022;71(11):2310–2334. https://doi.org/10.1007/s11172-022-3659-zKoroleva O.A., Dutikova Yu.V., Trubnikov A.V., et al. PROTAC: targeted drug strategy. Principles and limitations. Russ. Chem. Bull. https://doi.org/10.1007/s11172-022-3659-z [Original Russian Text: Koroleva O.A., Dutikova Yu.V., Trubnikov A.V., Zenov F.A., Manasova E.V., Shtil’ A.A., Kurkin A.V. PROTAC: targeted drug strategy. Principles and limitations. Izvestiya Akademii Nauk. Seriya khimicheskaya. 2022;71(11):2310–2334 (in Russ.).]Cao C., He M., Wang L., He Y., Rao Y. Chemistries of bifunctional PROTAC degraders. Chem. Soc. Rev. 2022;51(16):7066–7114. https://doi.org/10.1039/d2cs00220eCao C., He M., Wang L., He Y., Rao Y. Chemistries of bifunctional PROTAC degraders. Chem. Soc. Rev. 2022;51(16):7066–7114. https://doi.org/10.1039/d2cs00220eLiu Z., Hu M., Yang Y., Du C., Zhou H., Liu C., et al. An overview of PROTACs: a promising drug discovery paradigm. Mol. Biomed. 2022;3(1):46. https://doi.org/10.1186/s43556-022-00112-0Liu Z., Hu M., Yang Y., Du C., Zhou H., Liu C., et al. An overview of PROTACs: a promising drug discovery paradigm. Mol. Biomed. 2022;3(1):46. https://doi.org/10.1186/s43556-022-00112-0Yang N., Kong B., Zhu Z., Huang F., Zhang L., Lu T., et al. Recent advances in targeted protein degraders as potential therapeutic agents. Mol. Divers. 2024;28:309–333. https://doi.org/10.1007/s11030-023-10606-wYang N., Kong B., Zhu Z., Huang F., Zhang L., Lu T., et al. Recent advances in targeted protein degraders as potential therapeutic agents. Mol. Divers. 2024;28:309–333. https://doi.org/10.1007/s11030-023-10606-wLi S., Chen T., Liu J., Zhang H., Li J., Wang Z., et al. PROTACs: Novel tools for improving immunotherapy in cancer. Cancer Lett. 2023;560:216128. https://doi.org/10.1016/j.canlet.2023.216128Li S., Chen T., Liu J., Zhang H., Li J., Wang Z., et al. PROTACs: Novel tools for improving immunotherapy in cancer. Cancer Lett. 2023;560:216128. https://doi.org/10.1016/j.canlet.2023.216128Guedeney N., Cornu M., Schwalen F., Kieffer C., Voisin-Chiret A.S. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today. 2023;28(1):103395. https://doi.org/10.1016/j.drudis.2022.103395Guedeney N., Cornu M., Schwalen F., Kieffer C., Voisin-Chiret A.S. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today. 2023;28(1):103395. https://doi.org/10.1016/j.drudis.2022.103395Bricelj A., Steinebach C., Kuchta R., Gutschow M., Sosic I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front. Chem. 2021;9:707317. https://doi.org/10.3389/fchem.2021.707317Bricelj A., Steinebach C., Kuchta R., Gutschow M., Sosic I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front. Chem. 2021;9:707317. https://doi.org/10.3389/fchem.2021.707317Chamberlain P.P., Lopez-Girona A., Miller K., Carmel G., Pagarigan B., Chie-Leon B., et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 2014;21(9):803–809. https://doi.org/10.1038/nsmb.2874Chamberlain P.P., Lopez-Girona A., Miller K., Carmel G., Pagarigan B., Chie-Leon B., et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 2014;21(9):803–809. https://doi.org/10.1038/nsmb.2874Simpson L.M., Glennie L., Brewer A., Zhao J.F., Crooks J., Shpiro N., et al. Target protein localization and its impact on PROTAC-mediated degradation. Cell Chem. Biol. 2022;29(10):1482–1504.e7. https://doi.org/10.1016/j.chembiol.2022.08.004Simpson L.M., Glennie L., Brewer A., Zhao J.F., Crooks J., Shpiro N., et al. Target protein localization and its impact on PROTAC-mediated degradation. Cell Chem. Biol. 2022;29(10):1482–1504.e7. https://doi.org/10.1016/j.chembiol.2022.08.004Shah V.J., Đikić I. Localization matters in targeted protein degradation. Cell Chem. Biol. 2022;29(10):1465–1466. https://doi.org/10.1016/j.chembiol.2022.09.006Shah V.J., Đikić I. Localization matters in targeted protein degradation. Cell Chem. Biol. 2022;29(10):1465–1466. https://doi.org/10.1016/j.chembiol.2022.09.006Bemis T.A., La Clair J.J., Burkart M.D. Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras. J. Med. Chem. 2021;64(12):8042–8052. https://doi.org/10.1021/acs.jmedchem.1c00482Bemis T.A., La Clair J.J., Burkart M.D. Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras. J. Med. Chem. 2021;64(12):8042–8052. https://doi.org/10.1021/acs.jmedchem.1c00482Gadd M.S., Testa A., Lucas X., Chan K.H., Chen W., Lamont D.J., et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 2017;13(5):514–521. https://doi.org/10.1038/nchembio.2329Gadd M.S., Testa A., Lucas X., Chan K.H., Chen W., Lamont D.J., et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 2017;13(5):514–521. https://doi.org/10.1038/nchembio.2329Cao C., Yang J., Chen Y., Zhou P., Wang Y., Du W., et al. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. J. Med. Chem. 2020;63(19):11012–11033. https://doi.org/10.1021/acs.jmedchem.0c00821Cao C., Yang J., Chen Y., Zhou P., Wang Y., Du W., et al. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. J. Med. Chem. 2020;63(19):11012–11033. https://doi.org/10.1021/acs.jmedchem.0c00821Carmony K.C., Kim K.B. PROTAC-induced proteolytic targeting. In: Dohmen R., Scheffner M. (Eds.). Ubiquitin Family Modifiers and the Proteasome. Methods in Molecular Biology. Humana Press; 2012. V. 832. P. 627–638. https://doi.org/10.1007/978-1-61779-474-2_4419Carmony K.C., Kim K.B. PROTAC-induced proteolytic targeting. In: Dohmen R., Scheffner M. (Eds.). Ubiquitin Family Modifiers and the Proteasome. Methods in Molecular Biology. Humana Press; 2012. V. 832. P. 627–638. https://doi.org/10.1007/978-1-61779-474-2_4419Bondeson D.P., Smith B.E., Burslem G.M., Buhimschi A.D., Hines J., Jaime-Figueroa S., et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem. Biol. 2018;25(1):78–87.e5. https://doi.org/10.1016/j.chembiol.2017.09.010Bondeson D.P., Smith B.E., Burslem G.M., Buhimschi A.D., Hines J., Jaime-Figueroa S., et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem. Biol. 2018;25(1):78–87.e5. https://doi.org/10.1016/j.chembiol.2017.09.010Paiva S.L., Crews C.M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 2019;50:111–119. https://doi.org/10.1016/j.cbpa.2019.02.022Paiva S.L., Crews C.M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 2019;50:111–119. https://doi.org/10.1016/j.cbpa.2019.02.022Rao Z., Li K., Hong J., Chen D., Ding B., Jiang L., et al. A practical “preTACs-cytoblot” platform accelerates the streamlined development of PROTAC-based protein degraders. Eur. J. Med. Chem. 2023;251:115248. https://doi.org/10.1016/j.ejmech.2023.115248Rao Z., Li K., Hong J., Chen D., Ding B., Jiang L., et al. A practical “preTACs-cytoblot” platform accelerates the streamlined development of PROTAC-based protein degraders. Eur. J. Med. Chem. 2023;251:115248. https://doi.org/10.1016/j.ejmech.2023.115248Guo L., Zhou Y., Nie X., Zhang Z., Zhang Z., Li C., et al. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions. Eur. J. Med. Chem. 2022;236:114317. https://doi.org/10.1016/j.ejmech.2022.114317Guo L., Zhou Y., Nie X., Zhang Z., Zhang Z., Li C., et al. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions. Eur. J. Med. Chem. 2022;236:114317. https://doi.org/10.1016/j.ejmech.2022.114317Bhela I.P., Ranza A., Balestrero F.C., Serafini M., Aprile S., Di Martino R.M.C., et al. A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs. J. Med Chem. 2022;65(22):15282–15299. https://doi.org/10.1021/acs.jmedchem.2c01218Bhela I.P., Ranza A., Balestrero F.C., Serafini M., Aprile S., Di Martino R.M.C., et al. A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs. J. Med Chem. 2022;65(22):15282–15299. https://doi.org/10.1021/acs.jmedchem.2c01218Liu Z., Zhang Y., Xiang Y., Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. Molecules. 2022;27(17):5439. https://doi.org/10.3390/molecules27175439Liu Z., ZhangY., XiangY., Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. Molecules. 2022;27(17):5439. https://doi.org/10.3390/molecules27175439Li J., Chen X., Lu A., Liang C. Targeted protein degradation in cancers: Orthodox PROTACs and beyond. The Innovation. 2023;4(3):100413. https://doi.org/10.1016/j.xinn.2023.100413Li J., Chen X., Lu A., Liang C. Targeted protein degradation in cancers: Orthodox PROTACs and beyond. The Innovation. 2023;4(3):100413. https://doi.org/10.1016/j.xinn.2023.100413Yedla P., Babalghith A.O., Andra V.V., Syed R. PROTACs in the Management of Prostate Cancer. Molecules. 2023;28(9):3698. https://doi.org/10.3390/molecules28093698Yedla P., BabalghithA.O., AndraV.V., Syed R. PROTACs in the Management of Prostate Cancer. Molecules. 2023;28(9):3698. https://doi.org/10.3390/molecules28093698Gao X., Burris Iii H.A., Vuky J., Dreicer R., Sartor A.O., Sternberg C.N., et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2022;40(6_suppl):17–17. https://doi.org/10.1200/JCO.2022.40.6_suppl.017Gao X., Burris Iii H.A., Vuky J., Dreicer R., Sartor A.O., Sternberg C.N., et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2022;40(6_suppl):17–17. https://doi.org/10.1200/JCO.2022.40.6_suppl.017Ha S., Luo G., Xiang H. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives. J. Med. Chem. 2022;65(24):16128–16154. https://doi.org/10.1021/acs.jmedchem.2c01487Ha S., Luo G., Xiang H. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives. J. Med. Chem. 2022;65(24):16128–16154. https://doi.org/10.1021/acs.jmedchem.2c01487Hamilton E.P., Schott A.F., Nanda R., Lu H., Keung C.F., Gedrich R., et al. ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. J. Clin. Oncol. 2022;40(16_suppl):TPS1120–TPS1120. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS1120Hamilton E.P., Schott A.F., Nanda R., Lu H., Keung C.F., Gedrich R., et al. ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. J. Clin. Oncol. 2022;40(16_suppl):TPS1120–TPS1120. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS1120Xu H., Ohoka N., Yokoo H., Nemoto K., Ohtsuki T., Matsufuji H., et al. Development of Agonist-Based PROTACs Targeting Liver X Receptor. Front. Chem. 2021;9:674967. https://doi.org/10.3389/fchem.2021.674967Xu H., Ohoka N., Yokoo H., Nemoto K., Ohtsuki T., Matsufuji H., et al. Development of Agonist-Based PROTACs Targeting Liver X Receptor. Front. Chem. 2021;9:674967. https://doi.org/10.3389/fchem.2021.674967Yu F., Cai M., Shao L., Zhang J. Targeting Protein Kinases Degradation by PROTACs. Front. Chem. 2021;9:679120. https://doi.org/10.3389/fchem.2021.679120Yu F., Cai M., Shao L., Zhang J. Targeting Protein Kinases Degradation by PROTACs. Front. Chem. 2021;9:679120. https://doi.org/10.3389/fchem.2021.679120Dikic I., Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 2018;19(6):349–364. https://doi.org/10.1038/s41580-018-0003-4Dikic I., Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 2018;19(6):349–364. https://doi.org/10.1038/s41580-018-0003-4Takahashi D., Moriyama J., Nakamura T., Miki E., Takahashi E., Sato A., et al. AUTACs: Cargo-Specific Degraders Using Selective Autophagy. Mol. Cell. 2019;76(5):797–810.e10. https://doi.org/10.1016/j.molcel.2019.09.009TakahashiD., MoriyamaJ., NakamuraT., MikiE., TakahashiE., Sato A., et al. AUTACs: Cargo-Specific Degraders Using Selective Autophagy. Mol. Cell. 2019;76(5):797–810.e10. https://doi.org/10.1016/j.molcel.2019.09.009Li X., Liu Q., Xie X., Peng C., Pang Q., Liu B., et al. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research. J. Med. Chem. 2023;66(3):1700–1711. https://doi.org/10.1021/acs.jmedchem.2c01712Li X., Liu Q., Xie X., Peng C., Pang Q., Liu B., et al. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research. J. Med. Chem. 2023;66(3):1700–1711. https://doi.org/10.1021/acs.jmedchem.2c01712Li Z., Ma S., Zhang L., Zhang S., Ma Z., Du L., et al. Targeted Protein Degradation Induced by HEMTACs Based on HSP90. J. Med. Chem. 2023;66(1):733–751. https://doi.org/10.1021/acs.jmedchem.2c01648Li Z., Ma S., Zhang L., Zhang S., Ma Z., Du L., et al. Targeted Protein Degradation Induced by HEMTACs Based on HSP90. J. Med. Chem. 2023;66(1):733–751. https://doi.org/10.1021/acs.jmedchem.2c01648Brown K.J., Seol H., Pillai D.K., Sankoorikal B.J., Formolo C.A., Mac J., et al. The human secretome atlas initiative: implications in health and disease conditions. Biochim. Biophys. Acta. 2013;1834(11):2454–2461. https://doi.org/10.1016/j.bbapap.2013.04.007Brown K.J., Seol H., Pillai D.K., Sankoorikal B.J., Formolo C.A., Mac J., et al. The human secretome atlas initiative: implications in health and disease conditions. Biochim. Biophys. Acta. 2013;1834(11):2454–2461. https://doi.org/10.1016/j.bbapap.2013.04.007Banik S.M., Pedram K., Wisnovsky S., Ahn G., Riley N.M., Bertozzi C.R. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584(7820):291–297. https://doi.org/10.1038/s41586-020-2545-9Banik S.M., Pedram K., Wisnovsky S., Ahn G., Riley N.M., Bertozzi C.R. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584(7820):291–297. https://doi.org/10.1038/s41586-020-2545-9Caianiello D.F., Zhang M., Ray J.D., Howell R.A., Swartzel J.C., Branham E.M.J., et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat. Chem. Biol. 2021;17(9):947–953. https://doi.org/10.1038/s41589-021-00851-1Caianiello D.F., Zhang M., Ray J.D., Howell R.A., Swartzel J.C., Branham E.M.J., et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat. Chem. Biol. 2021;17(9):947–953. https://doi.org/10.1038/s41589-021-00851-1Ahn G., Banik S.M., Miller C.L., Riley N.M., Cochran J.R., Bertozzi C.R. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 2021;17(9):937–946. https://doi.org/10.1038/s41589-021-00770-1Ahn G., Banik S.M., Miller C.L., Riley N.M., Cochran J.R., Bertozzi C.R. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 2021;17(9):937–946. https://doi.org/10.1038/s41589-021-00770-1Wu Y., Lin B., Lu Y., Li L., Deng K., Zhang S., et al. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. Angew. Chem. Int. Ed. Engl. 2023;62(15):e202218106. https://doi.org/10.1002/anie.202218106Wu Y., Lin B., Lu Y., Li L., Deng K., Zhang S., et al. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. Angew. Chem. Int. Ed. Engl. 2023;62(15):e202218106. https://doi.org/10.1002/anie.202218106Kong L., Meng F., Wu S., Zhou P., Ge R., Liu M., et al. Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC. Clin. Transl. Med. 2023;13(2):e1191. https://doi.org/10.1002/ctm2.1191Kong L., Meng F., Wu S., Zhou P., Ge R., Liu M., et al. Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC. Clin. Transl. Med. 2023;13(2):e1191. https://doi.org/10.1002/ctm2.1191Dey S.K., Jaffrey S.R. RIBOTACs: Small Molecules Target RNA for Degradation. Cell Chem. Biol. 2019;26(8): 1047–1049. https://doi.org/10.1016/j.chembiol.2019.07.015Dey S.K., Jaffrey S.R. RIBOTACs: Small Molecules Target RNA for Degradation. Cell Chem. Biol. 2019;26(8): 1047–1049. https://doi.org/10.1016/j.chembiol.2019.07.015Childs-Disney J.L., Yang X., Gibaut Q.M.R., Tong Y., Batey R.T., Disney M.D. Targeting RNA structures with small molecules. Nat. Rev. Drug Discov. 2022;21(10):736–762. https://doi.org/10.1038/s41573-022-00521-4Childs-Disney J.L., Yang X., Gibaut Q.M.R., Tong Y., Batey R.T., Disney M.D. Targeting RNA structures with small molecules. Nat. Rev. Drug Discov. 2022;21(10):736–762. https://doi.org/10.1038/s41573-022-00521-4Costales M.G., Suresh B., Vishnu K., Disney M.D. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA. Cell Chem. Biol. 2019;26(8):1180–1186e5. https://doi.org/10.1016/j.chembiol.2019.04.008Costales M.G., Suresh B., Vishnu K., Disney M.D. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA. Cell Chem. Biol. 2019;26(8):1180–1186e5. https://doi.org/10.1016/j.chembiol.2019.04.008Borgelt L., Haacke N., Lampe P., Qiu X., Gasper R., Schiller D., et al. Small-molecule screening of ribonuclease L binders for RNA degradation. Biomed. Pharmacother. 2022;154:113589. https://doi.org/10.1016/j.biopha.2022.113589Borgelt L., Haacke N., Lampe P., Qiu X., Gasper R., Schiller D., et al. Small-molecule screening of ribonuclease L binders for RNA degradation. Biomed. Pharmacother. 2022;154:113589. https://doi.org/10.1016/j.biopha.2022.113589Ma S., Ji J., Tong Y., Zhu Y., Dou J., Zhang X., et al. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharm. Sin. B. 2022;12(7):2990–3005. https://doi.org/10.1016/j.apsb.2022.02.022Ma S., Ji J., Tong Y., Zhu Y., Dou J., Zhang X., et al. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharm. Sin. B. 2022;12(7):2990–3005. https://doi.org/10.1016/j.apsb.2022.02.022Gao H., Sun X., Rao Y. PROTAC Technology: Opportunities and Challenges. ACS Med. Chem. Lett. 2020;11(3):237–240. https://doi.org/10.1021/acsmedchemlett.9b00597Gao H., Sun X., Rao Y. PROTAC Technology: Opportunities and Challenges. ACS Med. Chem. Lett. 2020;11(3):237–240. https://doi.org/10.1021/acsmedchemlett.9b00597O’Brien Laramy M.N., Luthra S., Brown M.F., Bartlett D.W. Delivering on the promise of protein degraders. Nat. Rev. Drug Discov. 2023;22(5):410–427. https://doi.org/10.1038/s41573-023-00652-2O’Brien Laramy M.N., Luthra S., Brown M.F., Bartlett D.W. Delivering on the promise of protein degraders. Nat. Rev. Drug Discov. 2023;22(5):410–427. https://doi.org/10.1038/s41573-023-00652-2Cecchini C., Pannilunghi S., Tardy S., Scapozza L. From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation. Front. Chem. 2021;9:672267. https://doi.org/10.3389/fchem.2021.672267Cecchini C., Pannilunghi S., Tardy S., Scapozza L. From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation. Front. Chem. 2021;9:672267. https://doi.org/10.3389/fchem.2021.672267Liu X., Zhang X., Lv D., Yuan Y., Zheng G., Zhou D. Assays and technologies for developing proteolysis targeting chimera degraders. Future Med. Chem. 2020;12(12):1155–1179. https://doi.org/10.4155/fmc-2020-0073Liu X., Zhang X., Lv D., Yuan Y., Zheng G., Zhou D. Assays and technologies for developing proteolysis targeting chimera degraders. Future Med. Chem. 2020;12(12):1155–1179. https://doi.org/10.4155/fmc-2020-0073Pfaff P., Samarasinghe K.T.G., Crews C.M., Carreira E.M. Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. ACS Cent. Sci. 2019;5(10): 1682–1690. https://doi.org/10.1021/acscentsci.9b00713Pfaff P., Samarasinghe K.T.G., Crews C.M., Carreira E.M. Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. ACS Cent. Sci. 2019;5(10): 1682–1690. https://doi.org/10.1021/acscentsci.9b00713Zeng S., Zhang H., Shen Z., Huang W. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. Front. Chem. 2021;9:639176. https://doi.org/10.3389/fchem.2021.639176Zeng S., Zhang H., Shen Z., Huang W. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. Front. Chem. 2021;9:639176. https://doi.org/10.3389/fchem.2021.639176Liu J., Chen H., Liu Y., Shen Y., Meng F., Kaniskan H.U., et al. Cancer Selective Target Degradation by Folate-Caged PROTACs. J. Am. Chem. Soc. 2021;143(19):7380–7387. https://doi.org/10.1021/jacs.1c00451Liu J., Chen H., Liu Y., Shen Y., Meng F., Kaniskan H.U., et al. Cancer Selective Target Degradation by Folate-Caged PROTACs. J. Am. Chem. Soc. 2021;143(19):7380–7387. https://doi.org/10.1021/jacs.1c00451Gabizon R., Shraga A., Gehrtz P., Livnah E., Shorer Y., Gurwicz N., et al. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. J. Am. Chem. Soc. 2020;142(27):11734–11742. https://doi.org/10.1021/jacs.9b13907Gabizon R., Shraga A., Gehrtz P., Livnah E., Shorer Y., Gurwicz N., et al. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. J. Am. Chem. Soc. 2020;142(27):11734–11742. https://doi.org/10.1021/jacs.9b13907Yuan M., Chu Y., Duan Y. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy. Front. Chem. 2021;9:691093. https://doi.org/10.3389/fchem.2021.691093Yuan M., Chu Y., Duan Y. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy. Front. Chem. 2021;9:691093. https://doi.org/10.3389/fchem.2021.691093Jin Y., Fan J., Wang R., Wang X., Li N., You Q., et al. Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation. J. Am. Chem. Soc. 2023;145(13):7218–7229. https://doi.org/10.1021/jacs.2c12809Jin Y., Fan J., Wang R., Wang X., Li N., You Q., et al. Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation. J. Am. Chem. Soc. 2023;145(13):7218–7229. https://doi.org/10.1021/jacs.2c12809Morreale F.E., Kleine S., Leodolter J., Junker S., Hoi D.M., Ovchinnikov S., et al. BacPROTACs mediate targeted protein degradation in bacteria. Cell. 2022;185(13):2338–2353e18. https://doi.org/10.1016/j.cell.2022.05.009Morreale F.E., Kleine S., Leodolter J., Junker S., Hoi D.M., Ovchinnikov S., et al. BacPROTACs mediate targeted protein degradation in bacteria. Cell. 2022;185(13):2338–2353e18. https://doi.org/10.1016/j.cell.2022.05.009Gopal P., Dick T. Targeted protein degradation in antibacterial drug discovery? Prog. Biophys. Mol. Biol. 2020;152:10–14. https://doi.org/10.1016/j.pbiomolbio.2019.11.005Gopal P., Dick T. Targeted protein degradation in antibacterial drug discovery? Prog. Biophys. Mol. Biol. 2020;152:10–14. https://doi.org/10.1016/j.pbiomolbio.2019.11.005Sarathy J.P., Aldrich C.C., Go M.L., Dick T. PROTAC antibiotics: the time is now. Expert Opin. Drug Discov. 2023;18(4): 363–370. https://doi.org/10.1080/17460441.2023.2178413SarathyJ.P., AldrichC.C., GoM.L., DickT. PROTAC antibiotics: the time is now. Expert Opin. Drug Discov. 2023;18(4): 363–370. https://doi.org/10.1080/17460441.2023.2178413Venkatesan J., Murugan D., Rangasamy L. A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery. Antibiotics (Basel). 2022;11(12):1717. https://doi.org/10.3390/antibiotics11121717Venkatesan J., Murugan D., Rangasamy L. A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery. Antibiotics (Basel). 2022;11(12):1717. https://doi.org/10.3390/antibiotics11121717Espinoza-Chavez R.M., Salerno A., Liuzzi A., Ilari A., Milelli A., Uliassi E., et al. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery. ACS Bio Med. Chem. Au. 2023;3(1):32–45. https://doi.org/10.1021/acsbiomedchemau.2c00063Espinoza-Chavez R.M., Salerno A., Liuzzi A., Ilari A., Milelli A., Uliassi E., et al. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery. ACS Bio Med. Chem. Au. 2023;3(1):32–45. https://doi.org/10.1021/acsbiomedchemau.2c00063Desantis J., Goracci L. Proteolysis targeting chimeras in antiviral research. Future Med. Chem. 2022;14(7):459–462. https://doi.org/10.4155/fmc-2022-0005Desantis J., Goracci L. Proteolysis targeting chimeras in antiviral research. Future Med. Chem. 2022;14(7):459–462. https://doi.org/10.4155/fmc-2022-0005Ma Y., Frutos-Beltran E., Kang D., Pannecouque C., De Clercq E., Menendez-Arias L., et al. Medicinal chemistry strategies for discovering antivirals effective against drugresistant viruses. Chem. Soc. Rev. 2021;50(7):4514–4540. https://doi.org/10.1039/d0cs01084gMa Y., Frutos-Beltran E., Kang D., Pannecouque C., De Clercq E., Menendez-Arias L., et al. Medicinal chemistry strategies for discovering antivirals effective against drugresistant viruses. Chem. Soc. Rev. 2021;50(7):4514–4540. https://doi.org/10.1039/d0cs01084gReboud-Ravaux M., ElAmri C. COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies. Front. Drug Discov. 2022;2. https://doi.org/10.3389/fddsv.2022.892057Reboud-Ravaux M., ElAmri C. COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies. Front. Drug Discov. 2022;2. https://doi.org/10.3389/fddsv.2022.892057Li H., Wang S., Ma W., Cheng B., Yi Y., Ma X., et al. Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders. J. Med. Chem. 2022;65(10):7154–7169. https://doi.org/10.1021/acs.jmedchem.1c02013Li H., Wang S., Ma W., Cheng B., Yi Y., Ma X., et al. Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders. J. Med. Chem. 2022;65(10):7154–7169. https://doi.org/10.1021/acs.jmedchem.1c02013Li W., Yang F., Meng L., Sun J., Su Y., Shao L., et al. Synthesis, Structure Activity Relationship and Anti-influenza A Virus Evaluation of Oleanolic Acid-Linear Amino Derivatives. Chem. Pharm. Bull. (Tokyo). 2019;67(11):1201–1207. https://doi.org/10.1248/cpb.c19-00485Li W., Yang F., Meng L., Sun J., Su Y., Shao L., et al. Synthesis, Structure Activity Relationship and Anti-influenza A Virus Evaluation of Oleanolic Acid-Linear Amino Derivatives. Chem. Pharm. Bull. (Tokyo). 2019;67(11):1201–1207. https://doi.org/10.1248/cpb.c19-00485Xu Z., Liu X., Ma X., Zou W., Chen Q., Chen F., et al. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight. 2022;1(3):100030. https://doi.org/10.1016/j.cellin.2022.100030Xu Z., Liu X., Ma X., Zou W., Chen Q., Chen F., et al. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight. 2022;1(3):100030. https://doi.org/10.1016/j.cellin.2022.100030De Wispelaere M., Du G., Donovan K.A., Zhang T., Eleuteri N.A., Yuan J.C., et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 2019;10(1):3468. https://doi.org/10.1038/s41467-019-11429-wDe Wispelaere M., Du G., Donovan K.A., Zhang T., Eleuteri N.A., Yuan J.C., et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 2019;10(1):3468. https://doi.org/10.1038/s41467-019-11429-wHaniff H.S., Tong Y., Liu X., Chen J.L., Suresh B.M., Andrews R.J., et al. Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders. ACS Cent. Sci. 2020;6(10):1713–1721. https://doi.org/10.1021/acscentsci.0c00984Haniff H.S., Tong Y., Liu X., Chen J.L., Suresh B.M., Andrews R.J., et al. Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders. ACS Cent. Sci. 2020;6(10):1713–1721. https://doi.org/10.1021/acscentsci.0c00984Su X., Ma W., Feng D., Cheng B., Wang Q., Guo Z., et al. Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation. Angew. Chem. Int. Ed. Engl. 2021;60(40):21662–21667. https://doi.org/10.1002/anie.202105942Su X., Ma W., Feng D., Cheng B., Wang Q., Guo Z., et al. Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation. Angew. Chem. Int. Ed. Engl. 2021;60(40):21662–21667. https://doi.org/10.1002/anie.202105942Zhou Y., Zheng R., Liu D., Liu S., Disoma C., Li S., et al. UBR5 Acts as an Antiviral Host Factor against MERS-CoV via Promoting Ubiquitination and Degradation of ORF4b. J. Virol. 2022;96(17):e0074122. https://doi.org/10.1128/jvi.00741-22Zhou Y., Zheng R., Liu D., Liu S., Disoma C., Li S., et al. UBR5 Acts as an Antiviral Host Factor against MERS-CoV via Promoting Ubiquitination and Degradation of ORF4b. J. Virol. 2022;96(17):e0074122. https://doi.org/10.1128/jvi.00741-22Zhao J., Wang J., Pang X., Liu Z., Li Q., Yi D., et al. An antiinfluenza A virus microbial metabolite acts by degrading viral endonuclease PA. Nat. Commun. 2022;13(1):2079. https://doi.org/10.1038/s41467-022-29690-xZhao J., Wang J., Pang X., Liu Z., Li Q., Yi D., et al. An antiinfluenza A virus microbial metabolite acts by degrading viral endonuclease PA. Nat. Commun. 2022;13(1):2079. https://doi.org/10.1038/s41467-022-29690-xWild M., Kicuntod J., Seyler L., Wangen C., Bertzbach L.D., Conradie A.M., et al. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). Int. J. Mol. Sci. 2021;22(2):575. https://doi.org/10.3390/ijms22020575Wild M., Kicuntod J., Seyler L., Wangen C., Bertzbach L.D., Conradie A.M., et al. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). Int. J. Mol. Sci. 2021;22(2):575. https://doi.org/10.3390/ijms22020575Hahn F., Hamilton S.T., Wangen C., Wild M., Kicuntod J., Bruckner N., et al. Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. Int. J. Mol. Sci. 2021;22(23):12858. https://doi.org/10.3390/ijms222312858Hahn F., Hamilton S.T., Wangen C., Wild M., Kicuntod J., Bruckner N., et al. Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. Int. J. Mol. Sci. 2021;22(23):12858. https://doi.org/10.3390/ijms222312858Desantis J., Mercorelli B., Celegato M., Croci F., Bazzacco A., Baroni M., et al. Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur. J. Med. Chem. 2021;226:113814. https://doi.org/10.1016/j.ejmech.2021.113814Desantis J., Mercorelli B., Celegato M., Croci F., Bazzacco A., Baroni M., et al. Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur. J. Med. Chem. 2021;226:113814. https://doi.org/10.1016/j.ejmech.2021.113814Zahid S., Ali Y., Rashid S. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection. J. Biomol. Struct. Dyn. 2023;41(23):14566–14581. https://doi.org/10.1080/07391102.2023.2183037Zahid S., Ali Y., Rashid S. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection. J. Biomol. Struct. Dyn. 2023;41(23):14566–14581. https://doi.org/10.1080/07391102.2023.2183037Shaheer M., Singh R., Sobhia M.E. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2. J. Biomol. Struct. Dyn. 2022;40(21):10905–10917. https://doi.org/10.1080/07391102.2021.1953601Shaheer M., Singh R., Sobhia M.E. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2. J. Biomol. Struct. Dyn. 2022;40(21):10905–10917. https://doi.org/10.1080/07391102.2021.1953601

The authors declare that there are no conflicts of interest present.